Gene · 58508
Papers4,204
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 4,204
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study. | Genes (Basel) | 2022 | 36672847 | PubTator, text mining | PubMed |
| Approach to Cohort-Wide Re-Analysis of Exome Data in 1000 Individuals with Neurodevelopmental Disorders. | Genes (Basel) | 2022 | 36672771 | PubTator, text mining | PubMed |
| Prognostic analysis of RAS-related lncRNAs in liver hepatocellular carcinoma. | Ann Transl Med | 2022 | 36660710 | PubTator, text mining | PubMed |
| A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature. | Ann Transl Med | 2022 | 36660646 | PubTator, text mining | PubMed |
| Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. | J Thorac Dis | 2022 | 36647478 | PubTator, text mining | PubMed |
| A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma. | Transl Androl Urol | 2022 | 36632155 | PubTator, text mining | PubMed |
| Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. | Front Oncol | 2022 | 36620555 | PubTator, text mining | PubMed |
| Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma. | Front Pharmacol | 2022 | 36618928 | PubTator, text mining | PubMed |
| Genome-Wide Association Screening Determines Peripheral Players in Male Fertility Maintenance. | Int J Mol Sci | 2022 | 36613967 | PubTator, text mining | PubMed |
| Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. | Cancers (Basel) | 2022 | 36612206 | PubTator, text mining | PubMed |
| Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm. | Cells | 2022 | 36611899 | PubTator, text mining | PubMed |
| Pancreatic Cystic Lesions: A Focused Review on Cyst Clinicopathological Features and Advanced Diagnostics. | Diagnostics (Basel) | 2022 | 36611356 | PubTator, text mining | PubMed |
| Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates. | Front Oncol | 2022 | 36605429 | PubTator, text mining | PubMed |
| Rat and fish peripheral blood leukocytes respond distinctively to Anisakis pegreffii (Nematoda, Anisakidae) crude extract. | Front Cell Infect Microbiol | 2022 | 36590595 | PubTator, text mining | PubMed |
| Integrated molecular analyses of an interferon-γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. | Heliyon | 2022 | 36582677 | PubTator, text mining | PubMed |
| A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. | Cell Biosci | 2022 | 36581992 | PubTator, text mining | PubMed |
| Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report. | BMC Neurol | 2022 | 36581860 | PubTator, text mining | PubMed |
| Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer. | Front Immunol | 2022 | 36569935 | PubTator, text mining | PubMed |
| Integrative analysis indicates the prognostic value of circadian rhythm disruption in liver cancer: Potential for therapeutic targeting. | Front Immunol | 2022 | 36569894 | PubTator, text mining | PubMed |
| The different clinical facets of SYN1-related neurodevelopmental disorders. | Front Cell Dev Biol | 2022 | 36568968 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/58508/papers?page=46